It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
Masterkey-265 will test the sector’s renewed interest in oncolytic viruses as a way of turning “cold" tumours "hot”.
An adcom for Impulse Dynamics’ heart muscle stimulator is approaching, and the group will want to avoid a nasty shock.
Upcoming readout of the Keynote-522 trial could open up the neoadjuvant triple-negative breast cancer setting for the Merck & Co drug.
The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.
Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
Technology developed by GTX Medical has shown astonishing results in paralysed patients. Monetising it might be an even more impressive achievement.